Wednesday, November 30, 2016| Cataract Surgery, Inflammation, Laser photocoagulation, LASIK, Sun Pharma

EyewireTV - New FDA LASIK Data Revealed; BromSite Launched in US

In this week’s EyewireTV, a major government-sponsored study finds that the vast majority of LASIK patients are happy with their vision after surgery; however, a subset of patients experience new visual symptoms and Sun Pharma announces the US launch of BromSite (bromfenac ophthalmic solution) for the treatment of postoperative inflammation and prevention of ocular pain in patients undergoing cataract surgery. Also, OD-OS announces FDA 510(k) clearance of the Navilas 577s laser photocoagulator.

Watch Video

Tuesday, November 22, 2016| Allergan, Carl Zeiss Meditec, Clinical Trials, FDA Approval/Clearance, Glaucoma, Omidria, optical coherence tomography angiography, OCT angiography, Pediatric, PLEX Elite 9000, XEN

EyewireTV — XEN Glaucoma System Cleared by FDA; New OCT Angiography Platform

In this week’s EyewireTV, Allergan receives FDA clearance of the XEN Glaucoma Treatment System; and Carl Zeiss Meditec receives FDA clearance of the Zeiss PLEX Elite 9000, a swept-source OCT and OCT angiography platform. Also, in a post-marketing clinical trial, Omidria was shown to be safe and well tolerated in children undergoing cataract surgery.

Watch Video

Wednesday, November 16, 2016

EyewireTV - Novartis Considers Sale of Alcon; Dextenza Phase 3 Results

In this week’s EyewireTV, Novartis executives say they are considering a sale of the Alcon division; and Ocular Therapeutix announces positive topline results from its phase 3 clinical trial of Dextenza (dexamethasone insert 0.4 mg) for the treatment of postsurgical ocular inflammation and pain. Also, Pixium Vision announces the successful implantation and activation of its IRIS II bionic vision system in the UK.

Watch Video

Thursday, November 10, 2016

EyewireTV - Trump Impact on Health Care; Valeant Explores Eye Equipment Sale

In this week’s EyewireTV, after a surprising election result, a leading health care expert discusses the impact that Donald Trump's presidency could have on health care, patients, doctors, and the pharmaceutical industry; and Valeant reportedly explores a sale of its eye surgery equipment business—part of its Bausch + Lomb franchise—in an effort to pay down debt. Also, MillennialEYE hosts its 3rd annual live meeting in Miami, presenting a unique opportunity for the future leaders in ophthalmology and leading industry members to get together and discuss the future of the field.

Watch Video

Wednesday, November 02, 2016| Alcon, Allergan, Auven Therapeutics, Cataract Surgery, CyPass Micro-Stent, Drug Delivery, Dry Eye, Glaucoma, Sun Pharma

EyewireTV - Restasis Multidose Approved; Cypass Launch

In this week’s EyewireTV, Allergan receives approval from the FDA for Restasis Multidose, a new delivery system that allows patients to use the same preservative-free formulation of Restasis in a multidose bottle instead of single-use vials; and Alcon announces the official launch of the Cypass Micro-Stent, a minimally invasive glaucoma surgical device for use in combination with cataract surgery. Also, Sun Pharmaceutical obtains the rights to a dry eye disease candidate after acquiring Ocular Technologies Sarl, a portfolio company of private equity firm Auven Therapeutics.

Watch Video

Wednesday, October 26, 2016| Ophthalmology Innovation Summit

EyewireTV - CEOs Reveal What to Expect in Ophthalmology

In this week’s EyewireTV, several executives at the Ophthalmology Innovation Summit in Chicago provide EyewireTV an update on their companies and main product candidates.

Watch Video

Tuesday, October 18, 2016| aflibercept, Carl Zeiss Meditec, FDA Approval/Clearance, Ocular Therapeutix, Regeneron Pharmaceuticals, ReLEx SMILE, VisuMax femtosecond laser, Wet AMD

EyewireTV — Breaking Industry News Live from the AAO Meeting in Chicago

In this week’s EyewireTV, Ocular Therapeutix enters into a strategic collaboration with Regeneron Pharmaceuticals to develop a sustained-release formulation of aflibercept (Eylea) for the treatment of wet AMD and other retinal diseases; and Carl Zeiss Meditec showcases its VisuMax Femtosecond Laser ReLEx SMILE procedure for the first time since FDA approval last month.

Watch Video

Wednesday, October 12, 2016| Abbott Medical Optics, AMO, Anterior Segment, Astigmatism, Bausch+Lomb, Choroidal Neovascularization, CNV, Genentech, Pachymetry, Ranibizumab, Tecnis Toric IOL

EyewireTV - Lucentis for Myopic CNV; New B+L Topographer

In this week’s, the FDA accepts Genentech’s supplemental biologics license application and grants priority review for Lucentis (ranibizumab) for the treatment of myopic choroidal neovascularization; and Bausch + Lomb introduces the Orbscan 3 anterior segment analyzer, which offers surgeons the ability to examine anterior and posterior astigmatism and optical pachymetry. Also, Abbott releases the Tecnis toric calculator with posterior corneal astigmatism compensations.

Watch Video

Wednesday, October 05, 2016| Acquisitions, Mergers, Clinical Trials, Corneal Collagen Crosslinking, CXL, FDA Approval/Clearance, Katena Products, Regeneron Pharmaceuticals, Surgical Instruments, Wet AMD

EyewireTV — CXL Now Performed in US; Wet AMD Candidate Fails Trial

In this week’s EyewireTV, the first FDA-approved cross-linking procedures are now being performed in the United States; and in a mid-stage trial, Regeneron's combination therapy shows no benefit over Eylea alone for the treatment of wet AMD. Also, Katena Products, a provider of ophthalmic instruments, biologics, and devices, acquires ophthalmic instrument maker Eagle Vision.

Watch Video

Wednesday, September 28, 2016| Cataract Surgery, FDA Approval/Clearance, Glaucoma, Glaukos Corporation, Heidelberg Engineering, iStent, LASIK

EyewireTV — Long-Term LASIK Data; New iStent Studies

In this week’s EyewireTV, findings from a scientific literature review of more than 4,400 peer-reviewed clinical studies of LASIK over a 7-year period show the procedure is among the safest and most effective elective procedures available; and two studies support the effectiveness of the Glaukos iStent Trabecular Micro-Bypass both as a standalone procedure and when used in conjunction with cataract surgery. Also, Heidelberg Engineering receives FDA 510(k) clearance to market the Spectralis OCT Glaucoma Module Premium Edition in the United States.

Watch Video

Wednesday, September 21, 2016| Abbott Medical Optics, AMO, Acquisitions, Mergers, Aerie Pharmaceuticals, Clinical Trials, Glaucoma, Johnson & Johnson Vision Care, Myopia

EyewireTV — J&J Buys AMO; FDA Approves SMILE Procedure

In this week’s EyewireTV, in a major acquisition that will reshape the ophthalmic landscape, Johnson & Johnson agrees to acquire Abbott Medical Optics for about $4.3 billion in cash; and ophthalmologists in the United States will have an entirely new option in the surgical treatment of myopia as the FDA approves the ReLEx SMILE vision correction procedure. Also, Aerie Pharmaceuticals reports positive 90-day primary efficacy results of its phase 3 clinical trial (Mercury 1) for glaucoma candidate Roclatan.

Watch Video

Wednesday, September 14, 2016| Alcon, Carl Zeiss Meditec, FDA Approval/Clearance, IOL Implantation, Microincision Cataract Surgery, MICS, Myopia, Rayner Intraocular Lenses, ReLEx SMILE, VisuMax femtosecond laser

EyewireTV - Breaking Industry News from the EURETINA/ESCRS Meetings in Copenhagen

In this week’s EyewireTV, Carl Zeiss Meditec receives FDA approval of the VisuMax Femtosecond Laser ReLEx SMILE procedure, providing ophthalmologists in the United States an entirely new option in the surgical treatment of myopia; and Alcon launches a new visualization system for digitally assisted vitreoretinal surgery called the NGENUITY 3D. Also, Rayner releases its RayOne preloaded IOL injection system, which consists of a new microincision cataract surgery (MICS) lens and fully preloaded IOL injection system.

Watch Video

Wednesday, September 07, 2016| Acquisitions, Mergers, Allergan, Contact Lenses & Solutions, Glaucoma, RetroSense Therapeutics

EyewireTV — Allergan CEO Pledges Responsible Pricing; Contact Lens for Glaucoma

In this week’s EyewireTV, Allergan adds another clinical-stage biotech company to its portfolio after acquiring gene therapy company RetroSense Therapeutics; and in a blog post, Allergan President and CEO Brent Saunders pledges to put limits on the size and frequency of drug price hikes. Also, a contact lens designed to deliver medication could improve outcomes for patients with glaucoma and other conditions requiring treatment with eye drops.

Watch Video

Wednesday, August 31, 2016| Dry Eye, FDA Approval/Clearance, Meibomian Gland Dysfunction, MGD, Shire, TearScience

EyewireTV — US Commercial Launch of the Raindrop Inlay; Xiidra Now Available

In this week’s EyewireTV, the first commercial implantations of the Raindrop Near Vision Inlay are performed at the Slade & Baker Vision Center in Houston; and 6 weeks after receiving approval from the FDA, Shire's dry eye drug Xiidra (lifitegrast ophthalmic solution 5%) is now available by prescription in the United States. Also, a new study shows that a single TearScience LipiFlow treatment can deliver sustained mean improvement in meibomian gland function and dry eye symptoms through 12 months.

Watch Video

Wednesday, August 24, 2016| Antibiotics, Auven Therapeutics, Dry Eye, Intravitreal Injection, Technology

EyewireTV — Dry Eye Drug Candidate Advances; Topical Antibiotics Study

In this week’s EyewireTV, Auven Therapeutics completes patient enrollment in a phase 3 confirmatory study of its dry eye disease drug candidate Seciera (OTX-101); and new research shows that topical antibiotics may be unnecessary in patients receiving intravitreous injections when povidone-iodine is used to prevent endophthalmitis. Also, a new vision simulator could help patients see how the world would look with each type of IOL before they have surgery.

Watch Video
Load More